Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript

Core Points - Capricor Therapeutics is hosting a conference call to discuss the HOPE-3 Phase III Topline Data [1] Group 1 - The call is being led by AJ Bergmann, the Chief Financial Officer of Capricor [1]